Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Katelyn Gauger"'
Autor:
Sameem Abedin, Guru Subramanian Guru Murthy, Aniko Szabo, Mehdi Hamadani, Laura C. Michaelis, Karen-Sue Carlson, Lyndsey Runaas, Katelyn Gauger, Avinash G Desai, Mary M Chen, Alexandra M. Harrington, Ehab L. Atallah
Publikováno v:
Blood. 140:157-158
Autor:
Sameem M. Abedin, Talha Badar, Katelyn Gauger, Laura C. Michaelis, Lyndsey Runaas, Karen-Sue Carlson, GS Guru Murthy, Ehab Atallah
Publikováno v:
Leukemia Research. 123:106984
Autor:
Katelyn Gauger, Katrina Schroeder, Mehdi Hamadani, Taylor Keaton, Parameswaran Hari, Marcelo C. Pasquini, Saurabh Chhabra, Binod Dhakal, Carlos Arce-Lara, Anita D'Souza, Nirav N. Shah
Publikováno v:
Blood Cancer Journal, Vol 9, Iss 8, Pp 1-7 (2019)
Blood Cancer Journal
Blood Cancer Journal
In this phase I/II trial, BID, bendamustine (70, 80, or 90 mg/m2), ixazomib (4 mg), and dexamethasone (40 mg), was administered to 28 patients with relapsed and/or refractory multiple myeloma (RRMM) exposed to bortezomib and lenalidomide and refracto
Autor:
Katrina Schroeder, Marcelo C. Pasquini, Katelyn Gauger, Nirav N. Shah, Parameswaran Hari, Carlos Arce-Lara, Binod Dhakal, Mehdi Hamadani, Taylor Keaton, Saurabh Chhabra, Anita D'Souza
Publikováno v:
Blood. 132:1998-1998
Background: Bendamustine, a bifunctional alkylator with antimetabolite activity, is an attractive combination partner for both proteasome inhibitors (PI) and immunomodulators (ImiDs) in pts. with MM. This phase I/II trial assessed the safety and effi
Autor:
Anita D'Souza, Katrina Schroeder, Carlos Arce-Lara, Saurabh Chhabra, Katelyn Gauger, Marcelo C. Pasquini, Karen Crone, Mehdi Hamadani, Parameswaran Hari, Binod Dhakal
Publikováno v:
Journal of Clinical Oncology. 35:8012-8012
8012 Background: Bendamustine has promising activity in RRMM. This phase I (NCT02477215) study assessed the overall safety and activity of the combination of bendamustine with ixazomib & dexamethasone in pts. with MM pts. refractory to proteasome inh